ArticleTargeted oncology2021

Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial.

Céleste Lebbé et al.PubMed ↗Publisher ↗

No numbers read from the abstract.